GlassScriptPhysician profile
Erin M Dehaven
NPI 1518075852
$3,231.67
in general payments reported to CMS, 2019-2025
29 companies · $889 in 2025
The $889 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,688 · 2022: $14.53 · 2023: $167 · 2024: $473 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,529.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,676.36 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $240.24 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $215.73 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $168.15 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.14 | 2021-2025 | Jardiance |
| Mylan Specialty L.P. | $67.05 | 2024 | Yupelri |
| Lilly USA, LLC | $65.37 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Phathom Pharmaceuticals, INC. | $64.81 | 2024-2025 | Voquezna |
| Pfizer INC. | $59.04 | 2024-2025 | |
| Neuronetics, INC. | $56.35 | 2025 | Neurostar Tms Therapy System |
| Amgen INC. | $53.01 | 2024-2025 | Evenity, Prolia, Prolia |
| Janssen Pharmaceuticals, INC | $47.44 | 2024-2025 | Spravato |
| Astellas Pharma US INC | $46.52 | 2024-2025 | Veozah |
| Dexcom, INC. | $43.16 | 2024-2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $38.80 | 2025 | Eliquis |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $33.14 | 2023 | |
| Insulet Corporation | $27.98 | 2025 | Omnipod |
| Corcept Therapeutics | $27.94 | 2025 | Korlym |
| Hydrofera LLC | $27.39 | 2023 | Hydrofera Blue |
| Glaxosmithkline, LLC. | $22.92 | 2024 | Arexvy, Trelegy Ellipta |
| Boston Scientific Corporation | $22.84 | 2025 | Watchman Flx |
| Shield Therapeutics INC | $22.04 | 2024 | |
| Alnylam Pharmaceuticals INC. | $21.74 | 2024 | Amvuttra |
| Novartis Pharmaceuticals Corporation | $21.25 | 2025 | |
| Stryker Corporation | $20.85 | 2024 | Triathlon, Mako |
| Axsome Therapeutics, INC. | $20.25 | 2025 | Symbravo |
| Recor Medical INC | $19.47 | 2025 | Paradise Ultrasound Renal Denervation System |
| Organon LLC | $16.75 | 2025 | Nexplanon |
| Abbott Laboratories | $15.94 | 2024 | Proclaim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Dehaven listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.